查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1801138

2025 年至 2033 年气喘治疗市场规模、份额、趋势及预测（依药物类别、产品类型、治疗类型、给药途径及地区划分）

Asthma Therapeutics Market Size, Share, Trends and Forecast by Drug Class, Product Type, Treatment Type, Route of Administration, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球气喘治疗市场规模达188.3亿美元。展望未来， IMARC Group估计，到2033年，市场规模将达到221亿美元，2025年至2033年的复合年增长率为1.8%。目前，北美占据市场主导地位，2024年的市占率将超过50.0%。北美市场的成长得益于先进的医疗基础设施、高气喘盛行率、创新的治疗方案以及强劲的研发投入。由于广泛使用先进的生物製剂和联合疗法，加上有利于新产品审批的支持性监管框架，该地区在气喘治疗市场中占有相当大的份额。

全球气喘发病率不断上升，这得益于空气污染、过敏原、气候变迁等环境因素以及遗传因素，也催生了对更先进治疗方案的需求。此外，生物製剂和合併用药等新型疗法的出现正在改变气喘的治疗。这些疗法针对发炎和支气管收缩，为中度至重度气喘患者，尤其是对标准治疗无效的患者，提供了更佳的疗效和个人化治疗方案。此外，先进生物製剂和联合用药的应用日益广泛，尤其是在重度气喘患者中，这为气喘治疗市场带来了良好的前景。这些疗法，包括单株抗体，提供了精准的治疗方案，可显着改善患者的治疗效果。此外，政府机构和非政府组织 (NGO) 正在积极进行宣传活动，宣传早期发现和有效管理气喘的重要性，鼓励患者及时接受治疗并遵循处方疗法。

美国是市场中一个至关重要的细分市场，其驱动力源自于临床试验的成功，这些试验证明了新型疗法的有效性。积极的试验结果通常会促成突破性疗法的批准，从而满足尚未满足的医疗需求，尤其是在减少重度气喘发作和改善长期管理方面。这些创新为疗效树立了新的标准。 2024年，阿斯特捷利康公布了BATURA III期临床试验的积极结果，显示其急救吸入器AIRSUPRA(R)（沙丁胺醇/布地奈德）显着降低了间歇性或轻度持续性气喘患者发生重度气喘发作的可能性。由于疗效显着，该试验被提前终止。 AIRSUPRA是美国首个获准用于治疗气喘的抗发炎急救疗法。

气喘治疗市场趋势：

哮喘盛行率不断上升

全球气喘发病率不断上升，尤其是在已开发和都市化地区，这是推动气喘治疗市场需求的重要因素。世界卫生组织 (WHO) 表示，2019 年全球共有 2.62 亿人患有气喘，导致 45.5 万人死亡。空气污染、过敏原和气候变迁等环境因素，加上现代生活习惯，加剧了气喘的流行，尤其是在高收入国家和快速城市化地区。疾病负担的加重催生了对各种治疗方案的需求，从传统的吸入器到先进的生物製剂，再到轻度和重度气喘患者的标靶治疗。此外，对个人化医疗（针对特定个体的治疗方法）的重视，已成为药物研发创新的主要驱动力。随着人们不断努力减少气喘患者的住院率并改善其生活质量，预计市场将进一步成长，这得益于持续的研究投入和全球医疗保健服务覆盖率的改善。

治疗方案的进展

创新性气喘疗法，尤其是生物製剂和标靶疗法的开发，正在显着推进治疗方案的改进，并改善患者的预后。这些解决方案能够减少气道炎症，同时增强肺功能，使不同严重程度的气喘患者的管理更加有效。此外，医疗保健提供者和患者对生物製剂透过提高疗效和降低气喘发作率所带来的益处的认识不断提高，也促使其被越来越多地采用。气喘的高盛行率凸显了这些疗法的必要性。例如，根据美国疾病管制与预防中心2021年的报告，7.5%的5至11岁儿童患有气喘。正在进行的研究项目，加上突破性药物的监管授权，正在影响竞争环境，促进进步，并满足全球气喘患者尚未满足的需求。

提高认识和早期诊断

人们对气喘管理及早期发现的认识不断提高，推动了气喘治疗市场的发展。随着资讯和先进诊断设备的普及，人们的认识不断提高，患者也越来越渴望及时治疗，因此对正确治疗的需求也越来越高。医疗机构和政府制定了教育计划，加强对气喘控制措施的教育，使其更注重定期检查和后续治疗。数位健康平台和智慧吸入器等技术的进步使患者能够积极主动地进行疾病管理。随着新产品的推出，市场上尚未满足的医疗需求不断被满足。例如，2023年9月，欧盟批准了阿斯特捷利康的Tezspire（tezepelumab），用于治疗12岁以上使用高剂量吸入皮质类固醇仍无法充分控制病情的重症气喘患者。这些进展凸显了创新和认知在支持气喘治疗市场成长中的作用。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球气喘治疗市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依药品类别

  • 抗发炎药物
  • 支气管扩张剂
  • 联合疗法

第七章：市场区隔：依产品类型

  • 吸入器
    • 主要类型
      • 干粉吸入器
      • 定量吸入器
      • 软雾吸入器
  • 雾化器
    • 主要类型
      • 气动雾化器
      • 超音波雾化器
      • 网状雾化器

第八章：市场区隔：依治疗类型

  • 快速缓解药物
  • 长期气喘控制药物

第九章：市场细分：依行政途径

  • 吸入
  • 口服
  • 肠外

第十章：市场细分：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 11 章：SWOT 分析

第 12 章：价值链分析

第 13 章：波特五力分析

第 14 章：价格分析

第 15 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AstraZeneca PLC
    • Abbott Laboratories
    • Amgen Inc.
    • Biogen Inc.
    • Boehringer Ingelheim International GmbH
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline Plc
    • Merck Sharp & Dohme Corp.
    • Novartis International AG
    • Sunovion Pharmaceuticals Inc.
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112025A2338

The global asthma therapeutics market size was valued at USD 18.83 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 22.1 Billion by 2033, exhibiting a CAGR of 1.8% from 2025-2033. North America currently dominates the market, holding a market share of over 50.0% in 2024. The growth of the North American market is driven by advanced healthcare infrastructure, high asthma prevalence, innovative treatment options, and strong investment in research and development. The region holds a significant asthma therapeutics market share because of the extensive use of advanced biologics and combination therapies, coupled with supportive regulatory frameworks that favor new product approvals.

The increasing incidence of asthma globally, linked to environmental influences like air pollution, allergens, and climate shifts, along with genetic factors, is creating a demand for more sophisticated treatments. Additionally, the emergence of new treatments, such as biologics and combination medications, is transforming asthma care. These therapies target inflammation and bronchoconstriction, providing enhanced effectiveness and customized options for moderate to severe instances, particularly for individuals who do not respond to standard treatments. Furthermore, the increasing utilization of sophisticated biologics and combination treatments, especially for severe asthma situations, is offering a favorable asthma therapeutics market outlook. These therapies, including monoclonal antibodies, provide precise options that greatly enhance patient results. In addition, government bodies and non-governmental organizations (NGOs) are vigorously running awareness initiatives regarding the significance of early detection and effective management of asthma, motivating patients to pursue prompt treatment and follow prescribed therapies.

The United States is a crucial segment in the market, driven by the success of clinical trials demonstrating the efficacy of novel treatments. Positive trial results often lead to the approval of groundbreaking therapies that address unmet medical needs, particularly in reducing severe exacerbations and improving long-term management. These innovations set new standards in treatment efficacy. In 2024, AstraZeneca reported favorable outcomes from the BATURA Phase III trial, indicating that its rescue inhaler AIRSUPRA(R) (albuterol/budesonide) considerably lowered the likelihood of severe asthma attacks in individuals with intermittent or mild persistent asthma. The trial was halted prematurely because of remarkable effectiveness. AIRSUPRA is the inaugural anti-inflammatory rescue treatment authorized in the US for managing asthma.

Asthma Therapeutics Market Trends:

Increasing Prevalence of Asthma

The rising incidence of asthma globally, particularly in developed and urbanized regions, is a significant factor driving the asthma therapeutics market demand. The World Health Organization (WHO) states that in 2019, 262 million individuals suffered from asthma, leading to 455,000 fatalities. Environmental factors such as air pollution, allergens, and climate changes, coupled with modern lifestyle habits, have intensified the prevalence of asthma, especially in high-income nations and rapidly urbanizing regions. Increased disease burden creates a need for a variety of treatments ranging from conventional inhalers to advanced biologics and targeted therapies treating both mild and severe asthma patients. Moreover, the emphasis on personalized medicine, treatment approaches aimed at specific individuals, has acted as a major driver of innovations in drug discovery. With continuous endeavors to reduce hospitalization and improve the quality of life for asthma patients, the market is only expected to grow further, supported by continued investments in research and improved healthcare access worldwide.

Advancements in Treatment Options

Development of innovative asthma therapeutics, particularly biologics and targeted therapies, is advancing treatment options significantly and improving patient outcomes. The solutions are reducing airway inflammation while enhancing lung function, making the management of asthma in patients with different levels of severity more effective. Additionally, the increase in awareness about the benefits of biologics by health care providers and patients through increased efficacy and decreased exacerbation rates has resulted in its increased adoption. The high prevalence of asthma highlights the necessity for these therapies. For instance, as per the 2021 report by the US Centers for Disease Control and Prevention, 7.5% of children between the ages of 5 and 11 experienced asthma. Ongoing research initiatives, coupled with regulatory authorizations for groundbreaking medications, are influencing a competitive environment, fostering progress, and addressing the unfulfilled requirements of asthma sufferers globally.

Increasing Awareness and Early Diagnosis

Rising awareness about the management of asthma and the early detection of asthma have driven the asthma therapeutics market. As the awareness has improved with the accessibility of information and advanced diagnostic equipment, the patient has been seeking timely treatment and therefore a high demand for proper treatments. Healthcare organizations and the government develop educational programs that increase education on asthma control measures, making it even more a periodic check and following up with given therapies. The advancement in technology through digital health platforms and smart inhalers is enabling patients to be proactive in disease management. With the launch of new products, unmet medical needs continue to get addressed in the market. For example, in September 2023, the European Union approved AstraZeneca's Tezspire (tezepelumab) for the treatment of severe asthma in patients aged 12 and older who are inadequately controlled with high-dose inhaled corticosteroids. These developments underline the role of innovation and awareness in supporting the asthma therapeutics market growth.

Asthma Therapeutics Industry Segmentation:

Analysis by Drug Class:

  • Anti-Inflammatory Drugs
  • Bronchodilators
  • Combination Therapies

Combination therapies lead the market because of their effectiveness in tackling various aspects of asthma management in one treatment. These treatments often merge inhaled corticosteroids (ICS) with long-acting beta-agonists (LABAs), providing anti-inflammatory advantages and prolonged bronchodilation. Their dual-action mechanism offers both instant relief from airway constriction and diminishes chronic inflammation, rendering them very effective for moderate to severe asthma instances. The ease of having one therapy improves patient adherence and streamlines treatment plans, especially for individuals with ongoing symptoms. Improvements in formulation technology have facilitated the creation of more focused and long-lasting combination treatments, enhancing clinical results and reducing side effects. Pharmaceutical companies are focusing on launching new products, like triple-combination therapies, to enhance treatment choices. Regulatory approvals and favorable clinical data have strengthened healthcare providers' confidence in these therapies, reinforcing their position as the favored option for thorough asthma management.

Analysis by Product Type:

  • Inhalers
    • Dry Powder Inhalers
    • Metered Dose Inhalers
    • Soft Mist Inhalers
  • Nebulizers
    • Pneumatic Nebulizers
    • Ultrasonic Nebulizers
    • Mesh Nebulizers

Inhalers (dry powder inhalers, metered-dose inhalers, and soft mist inhalers), hold the biggest asthma therapeutics market share because of their extensive application and efficacy in directly administering medications to the lungs. Metered-dose inhalers are favored for their small size and accurate medication delivery, whereas dry powder inhalers provide user-friendliness without requiring propellants. Soft mist inhalers, featuring a fine mist and reliable dosing, serve patients who need a more gentle delivery method. The use of inhalers is motivated by their capacity for quick relief and sustained control, rendering them essential in the management of asthma. Innovations in technology, including smart inhalers equipped with digital tracking features, have improved treatment adherence and patient results. Furthermore, continuous advancements in formulation and device design are enhancing usability and effectiveness, making inhalers the preferred option for healthcare professionals and patients in asthma management.

Analysis by Treatment Type:

  • Quick-Relief Medications
  • Long-Term Asthma Control Medications

Long-term asthma control medications dominate the market due to their efficacy in controlling chronic asthma and decreasing both the occurrence and intensity of flare-ups. These drugs, such as inhaled corticosteroids, long-acting beta-agonists (LABAs), leukotriene modifiers, and biologics, aim to tackle the root inflammation and ensure stable lung performance over time. Their capacity to deliver reliable symptom control and enhance patients' quality of life establishes them as the foundation of asthma management approaches. Heightened awareness regarding the significance of consistent and preventive care has led to their common utilization. Improvements in biological treatments aimed at severe asthma cases, like monoclonal antibodies, have enhanced the segment's attractiveness by providing personalized and targeted solutions for patients not responding to conventional therapies. Pharmaceutical firms are actively funding research and development to launch novel combination medications and delivery systems, improving both effectiveness and patient compliance. Regulatory endorsements and broadened uses for biologics reinforce the sector's dominance in asthma treatments.

Analysis by Route of Administration:

  • Inhalation
  • Oral
  • Parenteral

Inhalers represent the largest segment, accounting 47.0% of the market share in 2024. Inhalation is the largest segment because it effectively administers medications straight to the lungs, providing quick symptom relief and improved treatment results. Inhaled treatments, such as corticosteroids, bronchodilators, and combination medications, are commonly favored for their targeted effects, which reduce systemic side effects relative to alternative methods of administration. The presence of different inhalation devices, including metered-dose inhalers, dry powder inhalers, and nebulizers, has enhanced patient compliance by providing choices suited to personal requirements. Advancements in technology, like smart inhalers equipped with digital tracking features, have increased the adoption of inhalation therapies by facilitating better asthma control through real-time monitoring of how medications are used. Regulatory approvals for novel formulations and the introduction of biosimilars in the inhalation sector have strengthened its dominance. Continual efforts by pharmaceutical companies to enhance the efficacy and convenience of inhaled medications strengthen their position as the primary choice for asthma treatment.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2024, North America held the largest market share, totaling 50.0%. North America dominates the market due to its strong healthcare infrastructure, significant research efforts, and widespread use of advanced medical technologies. The area gains from a significant presence of major pharmaceutical firms and solid regulatory structures that ease the approval and marketing of groundbreaking asthma therapies. Supportive healthcare policies and substantial government investment in respiratory disease research also enhance market expansion. Furthermore, the increasing incidence of asthma, influenced by environmental and genetic factors, has heightened the need for efficient treatment options. Furthermore, partnerships between academic institutions and industry stakeholders are driving the creation of innovative biologics and personalized medicine strategies, reinforcing North America's dominance in the asthma therapeutics sector. In 2024, Jasper Therapeutics announced that they have administered the first dose to a patient in the Phase 1b/2a ETESIAN clinical trial for briquilimab, a monoclonal antibody targeting c-Kit, designed for allergic asthma. The research will enroll 30 individuals from seven locations in Canada to evaluate the drug's efficacy, emphasizing mast cell reduction and respiratory response. The initial results are expected by the end of 2025.

Key Regional Takeaways:

United States Asthma Therapeutics Market Analysis

In North America, the United States represented 90.00% of the overall market share. In fact, the US asthma therapeutics market is growing with increased prevalence among people across different demographic categories. As highlighted by the CDC in 2020, almost 25 million people were estimated to be living with asthma in the U.S., further confirming the large number of affected populations. Also, adult women suffer disproportionately from asthma more than men do, indicating a need for individualized treatments for this demographic segment. More to this, children form a susceptible group, as per the Asthma and Allergy Foundation of America, where there are 5 million children asthmatic in the United States.

The high prevalence of asthma in adults and children is driving the demand for effective management strategies, including advanced inhalers, biologics, and combination therapies. Increased awareness about the importance of asthma control and early diagnosis has also encouraged more patients to seek medical intervention. These factors, coupled with ongoing innovation in asthma therapeutics, contribute to the expanding market in the United States, addressing the diverse needs of asthmatic patients across age groups.

Europe Asthma Therapeutics Market Analysis

The rising prevalence of asthma is fueling the asthma therapeutics market in Europe. Over 30 million adults and children are suffering from asthma in Europe, as has been reported by the European Lung Foundation, which clearly underlines the burden this chronic respiratory condition imposes. Women suffer more from asthma than men. This means there is a need for specific therapies that address the needs of this gender. Children, on the other hand, still form a susceptible population. The chronic illness, asthma, stands out as the most common condition among children in the region.

With the importance of early diagnosis and effective management surfacing awareness on advanced treatments such as biologics, combination therapies, and new inhalers, the overall need for this increase is coming out. Controlling asthma as proposed by national healthcare initiatives in Europe coupled with guidelines reinforces controlling asthma. Overall, along with the evolution in therapeutic options that are developing at a continued rate, asthma therapeutics demand will continue growing for all different groups of ages that suffer from it.

Asia Pacific Asthma Therapeutics Market Analysis

The Asia Pacific asthma therapeutics market is expanding fast, due to the increased incidence of asthma within the region. In China, asthma rates increased from 0.69% in 1984 to 5.30% in 2021, and it is estimated that they will rise up to 9.76% by 2050, according to BMC Public Health. The sharp increase indicates a great demand for the management of asthma in one of the region's largest populations. India also has a significant asthma burden. According to the NIH, 34.3 million cases of asthma have been reported in India, accounting for 13.09% of the global disease burden.

With prevalence continuously on the rise, asthma is a strongly developing market, in terms of need for advance therapy, in form of biologics and combination therapies. It is supplemented with next generation inhalers also. Greater emphasis towards early stage diagnosis and subsequent treatment has ensured their adoption, not to speak of government sponsored health care provisions and an up rising middle class looking forward to enhance access to care. All such factors together placed Asia Pacific region at the highest.

Latin America Asthma Therapeutics Market Analysis

The Latin America asthma therapeutics market is currently witnessing healthy growth due to a high and continuously rising prevalence of asthma in the region. Data published by industry reports in 2023 indicates that the overall prevalence of asthma in Latin America is about 17%, and the rates go up to as high as 30% in countries like Costa Rica. Thus, this area reflects a major unmet need for asthma management solutions appropriately addressed to the heterogeneous populations of the region.

With increased awareness of asthma as a chronic condition and its impact on quality of life, the demand for advanced therapeutics, such as inhalers, biologics, and combination therapies, has been increasing. Improved healthcare infrastructure and access to medical facilities in many Latin American countries further support the adoption of these therapies. The importance of early diagnosis and preventive care by governments and healthcare providers are significant factors that can mitigate asthma. Together, these aspects make the asthma therapeutic market in Latin America continue to grow.

Middle East and Africa Asthma Therapeutics Market Analysis

The asthma therapeutics market in the Middle East and Africa (MEA) is experiencing significant growth because of the high incidence of asthma and severe asthma in many nations throughout the region. According to industry reports, severe asthma rates are significantly high in African nations, with Kenya and Uganda showing 27% and Ethiopia at 19.9%. These statistics have created a significant burden of asthma-related health issues in the area, raising the need for efficient asthma management strategies.

Greater awareness of asthma as a chronic disease, coupled with better access to healthcare facilities, is driving adoption of advanced therapeutic options, such as inhalers, biologics, and targeted therapies. In addition, the increased interest in early diagnosis and personalized treatment plans, especially in urbanized regions, has helped manage asthma better. Such factors, coupled with the upgrading of healthcare infrastructure and government policies, are supporting the growth of the asthma therapeutics market in the Middle East and Africa.

Competitive Landscape:

Major market participants are concentrating on innovation, strategic alliances, and geographic growth to strengthen their market presence. They are making significant investments in research and development to launch advanced biologics and combination therapies that enhance efficacy and patient adherence. Businesses are also utilizing digital health technologies, like smart inhalers and mobile apps, to better monitor and manage asthma symptoms. Regulatory authorizations for new formulations and biosimilars are being sought to enhance product portfolios. Collaborative alliances with academic institutions and biotech firms are aiding in the discovery of new therapeutic approaches. In 2024, Teva Pharmaceuticals announced a clinical collaboration with Abingworth, securing as much as $150M in funding to advance TEV-248, a late-stage asthma rescue inhaler that combines ICS/SABA for adult and pediatric patients. Launch Therapeutics will carry out clinical trials, while Teva will focus on production and marketing. This aligns with Teva's "Pivot to Growth" strategy, emphasizing the pipeline's expansion.

The report provides a comprehensive analysis of the competitive landscape in the asthma therapeutics market with detailed profiles of all major companies, including:

  • AstraZeneca PLC
  • Abbott Laboratories
  • Amgen Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck Sharp & Dohme Corp.
  • Novartis International AG
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

  • 1.How big is the asthma therapeutics market?
  • 2.What is the future outlook of asthma therapeutics market?
  • 3.What are the key factors driving the asthma therapeutics market?
  • 4.Which region accounts for the largest asthma therapeutics market share?
  • 5.Which are the leading companies in the global asthma therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Asthma Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Anti-Inflammatory Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Bronchodilators
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Combination Therapies
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Product Type

  • 7.1 Inhalers
    • 7.1.1 Market Trends
    • 7.1.2 Major Types
      • 7.1.2.1 Dry Powder Inhalers
      • 7.1.2.2 Metered Dose Inhalers
      • 7.1.2.3 Soft Mist Inhalers
    • 7.1.3 Market Forecast
  • 7.2 Nebulizers
    • 7.2.1 Market Trends
    • 7.2.2 Major Types
      • 7.2.2.1 Pneumatic Nebulizers
      • 7.2.2.2 Ultrasonic Nebulizers
      • 7.2.2.3 Mesh Nebulizers
    • 7.2.3 Market Forecast

8 Market Breakup by Treatment Type

  • 8.1 Quick-Relief Medications
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Long-Term Asthma Control Medications
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Inhalation
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Oral
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Parenteral
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AstraZeneca PLC
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Abbott Laboratories
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Amgen Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Biogen Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Boehringer Ingelheim International GmbH
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 F. Hoffmann-La Roche Ltd.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 SWOT Analysis
    • 15.3.7 GlaxoSmithKline Plc
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Merck Sharp & Dohme Corp.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Novartis International AG
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Sunovion Pharmaceuticals Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 SWOT Analysis
    • 15.3.11 Teva Pharmaceutical Industries Ltd.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Asthma Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Asthma Therapeutics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Asthma Therapeutics Market: Breakup by Drug Class (in %), 2024
  • Figure 4: Global: Asthma Therapeutics Market: Breakup by Product Type (in %), 2024
  • Figure 5: Global: Asthma Therapeutics Market: Breakup by Treatment Type (in %), 2024
  • Figure 6: Global: Asthma Therapeutics Market: Breakup by Route of Administration (in %), 2024
  • Figure 7: Global: Asthma Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Asthma Therapeutics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 9: Global: Asthma Therapeutics (Anti-Inflammatory Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Asthma Therapeutics (Anti-Inflammatory Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Asthma Therapeutics (Bronchodilators) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Asthma Therapeutics (Bronchodilators) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Asthma Therapeutics (Combination Therapies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Asthma Therapeutics (Combination Therapies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Asthma Therapeutics (Inhalers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Asthma Therapeutics (Inhalers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Asthma Therapeutics (Nebulizers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Asthma Therapeutics (Nebulizers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Asthma Therapeutics (Quick-Relief Medications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Asthma Therapeutics (Quick-Relief Medications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Asthma Therapeutics (Long-Term Asthma Control Medications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Asthma Therapeutics (Long-Term Asthma Control Medications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Asthma Therapeutics (Inhalation) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Asthma Therapeutics (Inhalation) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Asthma Therapeutics (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Asthma Therapeutics (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Asthma Therapeutics (Parenteral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Asthma Therapeutics (Parenteral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: North America: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: North America: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: United States: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: United States: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Canada: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Canada: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Asia Pacific: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Asia Pacific: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: China: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: China: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Japan: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Japan: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: India: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: India: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: South Korea: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: South Korea: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Australia: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Australia: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Indonesia: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Indonesia: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Others: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Others: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Europe: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Europe: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Germany: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Germany: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: France: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: France: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: United Kingdom: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: United Kingdom: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Italy: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Italy: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Spain: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Spain: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Russia: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Russia: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Others: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Others: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Latin America: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Latin America: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Brazil: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Brazil: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Mexico: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Mexico: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Others: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Others: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Middle East and Africa: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Middle East and Africa: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Global: Asthma Therapeutics Industry: SWOT Analysis
  • Figure 78: Global: Asthma Therapeutics Industry: Value Chain Analysis
  • Figure 79: Global: Asthma Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Asthma Therapeutics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Asthma Therapeutics Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 3: Global: Asthma Therapeutics Market Forecast: Breakup by Product Type (in Million USD), 2025-2033
  • Table 4: Global: Asthma Therapeutics Market Forecast: Breakup by Treatment Type (in Million USD), 2025-2033
  • Table 5: Global: Asthma Therapeutics Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 6: Global: Asthma Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Asthma Therapeutics Market Structure
  • Table 8: Global: Asthma Therapeutics Market: Key Players